Ascentage Pharma to Present Olverembatinib Data
Ascentage Pharma, a prominent global biopharmaceutical company, is preparing to unveil updated clinical data on its groundbreaking drug candidate, olverembatinib, at the esteemed ESMO Congress. This presentation will concentrate on the treatment of patients suffering from succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST). The event underscores the significant progress being made in oncology research and the treatment options available to patients.
ESMO Congress: A Hub for Innovative Research
The ESMO Congress is well-known for highlighting the latest advancements in cancer research and treatment approaches from around the world. It gathers experts from diverse fields to discuss recent findings, making it a vital event for oncologists and researchers alike. Attending this year's congress is expected to be enlightening, further advancing the development of cancer therapies.
Olverembatinib: A Game-Changing Treatment Strategy
Olverembatinib, a third-generation Tyrosine Kinase Inhibitor (TKI) developed by Ascentage Pharma, is gaining attention for its clinical applications. Recently, the China CDE has approved the drug to initiate a registrational Phase III study. This significant achievement reflects Ascentage's dedication to advancing clinical development and broadening treatment options for patients globally.
Details of the Presentation
The Mini Oral presentation will include the following details:
- **Format:** Mini oral
- **Presentation #:** 1722MO
- **Category:** Sarcoma
- **Date & Time:** Friday, September 13, 2024, 16:30 - 16:35 CEST
- **Speaker:** Dr. Haibo Qiu, MD, PhD, from Sun Yat-sen University Cancer Center
About Ascentage Pharma
Ascentage Pharma has established itself as a leading biopharmaceutical organization. The company is dedicated to discovering and developing therapies that address unmet medical needs, particularly in the field of cancer. Its diverse pipeline includes powerful Bcl-2 inhibitors and next-generation TKIs, which are essential in combating various malignancies.
Clinical Trials and Regulatory Achievements
So far, Ascentage Pharma has conducted over 40 clinical trials in multiple countries and has successfully navigated the regulatory landscape. The company has received several designations, including Priority Review and Breakthrough Therapy Designations for olverembatinib, highlighting its potential to significantly impact the treatment of chronic myeloid leukemia (CML) and beyond.
Enhancing Research and Development
By fostering collaborations with esteemed institutions and biotech companies, Ascentage Pharma has strengthened its research capabilities. The company aims to meet unmet clinical needs both locally and globally, enhancing its R&D efforts and refining its clinical development processes, which will ultimately benefit patients everywhere.
Frequently Asked Questions
What is the purpose of Ascentage Pharma's presentation at ESMO 2024?
The presentation aims to share updated clinical data on olverembatinib for patients with SDH-deficient GIST, underlining its therapeutic potential.
When and where is the ESMO Congress taking place?
The ESMO Congress is scheduled from September 13 to 17, 2024, with Ascentage Pharma's presentation happening on September 13.
What is olverembatinib and its relevance in cancer treatment?
Olverembatinib is a third-generation TKI designed to treat drug-resistant CML and SDH-deficient GIST, showing promising results in clinical trials.
Who will present the data on olverembatinib?
The presentation will be conducted by Dr. Haibo Qiu of Sun Yat-sen University Cancer Center.
How is Ascentage Pharma contributing to cancer research?
Ascentage Pharma is committed to developing innovative therapies for malignancies, engaging in numerous clinical trials and collaborating with leading institutions.
